Intuitive's da Vinci 5 Surgical System receives CE mark approval for minimally invasive surgery in Europe, enhancing surgical capabilities and efficiency.
Quiver AI Summary
Intuitive Surgical has announced that its da Vinci 5 Surgical System has received CE mark approval for use in Europe in both adult and pediatric minimally invasive endoscopic procedures. This system is the most advanced in the da Vinci series, featuring over 150 enhancements to improve surgical outcomes, efficiency, and provide actionable insights through a powerful intelligent platform. The da Vinci 5 offers unique features including Force Feedback technology and an ergonomic surgeon console, enhancing both patient care and the surgeon's experience. With this approval, Intuitive aims to support healthcare systems across Europe by providing innovative, high-quality surgical solutions, building on its legacy of success which includes nearly 17 million procedures performed globally. The company celebrated its 30th anniversary in advancing robotic-assisted technology aimed at better patient outcomes and reduced healthcare costs.
Potential Positives
- Da Vinci 5 Surgical System has received CE mark approval for extensive use in Europe, allowing the company to enhance its market presence and accessibility.
- The system features over 150 enhancements and advanced technologies aimed at improving surgical outcomes, operational efficiency, and surgeon experience.
- Providing healthcare systems in Europe with an expanded portfolio of da Vinci systems supports greater choice and flexibility for medical professionals, ultimately aiming to improve patient care.
- The announcement marks the 30th anniversary of Intuitive's development of robotic-assisted technology, highlighting the company's long-standing commitment to innovation in minimally invasive care.
Potential Negatives
- Potential risks associated with regulatory approvals and market reception are highlighted, which could impact future performance.
- The press release contains extensive forward-looking statements, indicating uncertainty about product performance and market conditions.
- The mention of "known and unknown risks" suggests vulnerabilities that could affect investor confidence.
FAQ
What is the da Vinci 5 Surgical System?
The da Vinci 5 Surgical System is Intuitive's latest robotic-assisted surgical platform, designed for minimally invasive procedures in various specialties.
What procedures can the da Vinci 5 perform?
The da Vinci 5 can be used for abdominopelvic and thoracoscopic procedures, including urologic, gynecologic, and general laparoscopic surgeries.
When did the da Vinci 5 receive CE mark approval?
The da Vinci 5 Surgical System received CE mark approval on July 2, 2025, allowing its use in Europe.
What enhancements does da Vinci 5 offer?
Da Vinci 5 features over 150 enhancements, including Force Feedback technology, superior 3D vision, and improved surgeon console ergonomics.
How many procedures have been performed with Intuitive systems?
As of 2024, nearly 17 million procedures have been performed worldwide using Intuitive's surgical technologies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ISRG Congressional Stock Trading
Members of Congress have traded $ISRG stock 11 times in the past 6 months. Of those trades, 3 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 1 purchase worth up to $50,000 on 05/08 and 2 sales worth up to $100,000 on 05/12, 04/07.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 0 purchases and 4 sales worth up to $60,000 on 04/09, 01/29, 01/21, 01/10.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 04/07.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 01/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ISRG Insider Trading Activity
$ISRG insiders have traded $ISRG stock on the open market 67 times in the past 6 months. Of those trades, 0 have been purchases and 67 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by insiders over the last 6 months:
- DAVID J. ROSA (President) has made 0 purchases and 2 sales selling 16,509 shares for an estimated $9,204,142.
- BRIAN EDWARD MILLER (EVP & Chief Digital Officer) has made 0 purchases and 5 sales selling 12,900 shares for an estimated $6,365,341.
- ROBERT DESANTIS (EVP & Chief Strategy & Corp Op) has made 0 purchases and 14 sales selling 12,535 shares for an estimated $6,271,994.
- MYRIAM CURET (EVP & Chief Medical Officer) has made 0 purchases and 4 sales selling 9,840 shares for an estimated $5,438,101.
- JAMIE SAMATH (See Remarks) has made 0 purchases and 15 sales selling 8,462 shares for an estimated $4,817,912.
- AMY L LADD has made 0 purchases and 6 sales selling 8,926 shares for an estimated $4,521,660.
- AMAL M JOHNSON sold 4,635 shares for an estimated $2,626,191
- GARY LOEB (EVP & Chief Legal and Complian) has made 0 purchases and 3 sales selling 4,300 shares for an estimated $2,390,260.
- MARK BROSIUS (SVP & Chief Mfg and Supply Cha) has made 0 purchases and 15 sales selling 3,641 shares for an estimated $2,025,818.
- JAMI K NACHTSHEIM sold 2,400 shares for an estimated $1,248,000
- FREDRIK WIDMAN (VP Corporate Controller) sold 810 shares for an estimated $464,761
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ISRG Hedge Fund Activity
We have seen 1,098 institutional investors add shares of $ISRG stock to their portfolio, and 816 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 1,576,385 shares (-15.5%) from their portfolio in Q1 2025, for an estimated $780,736,198
- GQG PARTNERS LLC removed 1,145,300 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $567,232,731
- FMR LLC removed 1,089,681 shares (-10.1%) from their portfolio in Q1 2025, for an estimated $539,686,308
- PROFICIO CAPITAL PARTNERS LLC removed 948,095 shares (-99.8%) from their portfolio in Q1 2025, for an estimated $469,563,010
- FISHER ASSET MANAGEMENT, LLC removed 821,665 shares (-16.9%) from their portfolio in Q1 2025, for an estimated $406,946,024
- PRICE T ROWE ASSOCIATES INC /MD/ removed 686,369 shares (-4.7%) from their portfolio in Q1 2025, for an estimated $339,937,974
- BAILLIE GIFFORD & CO removed 608,415 shares (-16.1%) from their portfolio in Q1 2025, for an estimated $301,329,697
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ISRG Analyst Ratings
Wall Street analysts have issued reports on $ISRG in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Deutsche Bank issued a "Sell" rating on 06/09/2025
- Citigroup issued a "Buy" rating on 05/22/2025
- Piper Sandler issued a "Overweight" rating on 04/23/2025
- BTIG issued a "Buy" rating on 04/14/2025
- UBS issued a "Overweight" rating on 01/29/2025
- Morgan Stanley issued a "Overweight" rating on 01/16/2025
- Bernstein issued a "Outperform" rating on 01/08/2025
To track analyst ratings and price targets for $ISRG, check out Quiver Quantitative's $ISRG forecast page.
$ISRG Price Targets
Multiple analysts have issued price targets for $ISRG recently. We have seen 2 analysts offer price targets for $ISRG in the last 6 months, with a median target of $582.5.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $560.0 on 04/14/2025
- An analyst from Truist Financial set a target price of $605.0 on 03/17/2025
Full Release
SUNNYVALE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the da Vinci 5 Surgical System has received CE mark approval for adult and pediatric use in Europe for minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic surgical procedures, including urologic, gynecologic, and general laparoscopic procedures.
Da Vinci 5 is Intuitive’s most advanced and integrated multiport robotic-assisted surgical system, building on the da Vinci Xi Surgical System’s highly functional design.
It features more than 150 enhancements and joins a portfolio of da Vinci surgical systems that surgeons have used in more than 410,000 procedures in Europe in 2024 and nearly 17 million procedures worldwide to date.
“We are pleased that our da Vinci 5 Surgical System has received CE mark approval, marking its entry to Europe,” said Intuitive Chief Executive Officer Dave Rosa.
“At Intuitive, we’re focused on providing healthcare systems across Europe and around the world with thoughtful innovation that solves problems today and into the future. After over a decade of careful development, da Vinci 5 is the most advanced and integrated platform we’ve ever created – designed to enable better outcomes, efficiency, and insights for the future of minimally invasive care,” said Rosa.
Da Vinci 5 is designed to deliver:
- Enhanced surgical senses to support better patient outcomes , including first-of-its-kind Force Feedback enabled technology, the most realistic 3D da Vinci vision system to date, and an ergonomic, immersive surgeon console to support surgeon career longevity.
- Operational efficiency, through greater surgeon autonomy with the integration of key components that surgeons can control at their fingertips, and by streamlining workflow with an easy-to-learn system, a universal user interface for care teams, and dynamic assistance integrated into the system to automate select tasks.
-
Actionable insights
through an intelligent platform with 10,000x more computing power and new sensors, software, and advanced processors – providing surgeons with more useable data to help them quantify, understand, and improve their surgical performance for patients.
“We believe that the operational efficiencies and actionable insights provided by da Vinci 5 will not only help transform surgery but also help address critical challenges faced by healthcare systems across Europe,” said Dirk Barten, Intuitive senior vice president and general manager for Europe.
“It's exciting that surgeons and care teams across Europe will have their choice of the full portfolio of da Vinci systems, including da Vinci 5, giving them greater choice and flexibility, and ultimately supporting quality care for more patients across the region,” said Barten.
In 2024, the U.S. Food and Drug Administration cleared the da Vinci 5 Surgical System for use during urology, general, gynecology, and thoracic procedures in adults.
Da Vinci 5 is the fifth generation da Vinci surgical system and the latest addition to the da Vinci family. This includes multiport systems da Vinci X and da Vinci Xi, and the single port system da Vinci SP, offering surgeons and hospitals their choice of highly capable, proven solutions from Intuitive.
2025 marks Intuitive’s 30th year developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons have performed nearly 17 million procedures using our technology and nearly 90,000 surgeons have been trained to use our systems worldwide.
Contact
Megan Elliott, Intuitive
(669) 222-9899
[email protected]
About Intuitive Surgical, Inc.
Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
For more information, please visit: http://www.intuitive.com/safety
About da Vinci surgical systems
There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialised instrumentation, including a miniaturised surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
Forward-Looking Statements
This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “can,” “could,” “should,” “would,” “targeted,” “potential,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive’s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, obtaining of regulatory approvals, technical, clinical, and other performance of products and services, and making products and services available to more patients and health care professionals. These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive’s Annual Reports and other filings with relevant securities regulators.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in Intuitive’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive’s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.